Infectious Disease
Emergent wins $75m BARDA contact for anthrax vaccine
Emergent BioSolutions has secured a $75m contract for the acquisition of the FDA-approved anthrax vaccine, Cyfendus. The contract was awarded…
Boehringer to leverage IBM’s technologies for antibody discovery
Boehringer Ingelheim has entered an agreement with IBM to leverage the latter’s foundation model technologies for novel antibody discovery and…
Japan approves Daiichi Sankyo’s Covid-19 booster vaccine
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Daiichi Sankyo’s Omicron XBB.1.5-adapted monovalent mRNA [messenger ribonucleic acid] vaccine,…
Everest Medicines gains NMPA approval in China for IgAN therapy
Everest Medicines has received approval from China's National Medical Products Administration for its therapy, Nefecon, to treat primary immunoglobulin A…
China’s NMPA approves ArkBio’s RSV neutralising antibody drug
China’s National Medical Products Administration (NMPA) has approved Shanghai Ark Biopharmaceutical’s (ArkBio) investigational new drug application for its respiratory syncytial…
Daiichi Sankyo signs agreement with Japan to supply Covid-19 vaccine
Daiichi Sankyo has signed an agreement with Japan’s Ministry of Health, Labour and Welfare (MHLW) to deliver 1.4 million doses…
Micron Biomedical receives funds to produce needle-free vaccines
US-based Micron Biomedical has received $23.6m in funding from the Bill & Melinda Gates Foundation for the bulk manufacturing of needle-free vaccines.…
UK JCVI recommends chickenpox vaccine in early childhood
The UK's Joint Committee on Vaccination and Immunisation (JCVI) has recommended the addition of a chickenpox vaccine to the country's routine…
Valneva wins FDA approval for the first chikungunya vaccine
The US Food and Drug Administration (FDA) has granted accelerated approval to the first chikungunya vaccine, Valneva’s Ixchiq. Ixchiq is…
Gilead posts rise in Q3 2023 net income to $2.17bn
Gilead Sciences has posted a net income of $2.17bn for the third quarter (Q3) of 2023 compared with $1.78bn in the same…
